Showing results (41-50 of 144) with videos related to
Sort By:
Pageof 15
American Journal of Hypertension|November 16, 2014
Prediction of cardiovascular and all-cause mortality at 10 years in the hypertensive aged populationQuan L Huynh, Christopher M Reid, Enayet K Chowdhury, et al.Environmental Health Perspectives|March 21, 2015
Forest Fire Smoke Exposures and Out-of-Hospital Cardiac Arrests in Melbourne, Australia: A Case-Crossover StudyMartine Dennekamp, Lahn D Straney, Bircan Erbas, et al.Circulation|April 6, 2005
White blood cell count predicts reduction in coronary heart disease mortality with pravastatinRalph A H Stewart, Harvey D White, Adrienne C Kirby, et al.The Medical Journal of Australia|October 17, 2002
Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?Paul P Glasziou, Simon D Eckermann, Sarah E Mulray, et al.Diabetes Research and Clinical Practice|January 26, 2010
Waist circumference has heterogeneous impact on development of diabetes in different populations: longitudinal comparative study between Australia and IranNassir Rostambeigi, Jonathan E Shaw, Robert C Atkins, et al.Geroscience|August 23, 2023
Sex-dependent associations of plasma high-density lipoprotein cholesterol and mortality risk in healthy older men and women: two prospective cohort studiesSultana Monira Hussain, Andrew M Tonkin, Gerald F Watts, et al.The Lancet. Healthy Longevity|March 7, 2022
Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trialRakibul M Islam, Robin J Bell, David J Handelsman, et al.Clinical Pharmacology and Therapeutics|June 21, 2020
Genetic Variation in PEAR1, Cardiovascular Outcomes and Effects of Aspirin in a Healthy Elderly PopulationJoshua P Lewis, Moeen Riaz, Sophia Xie, et al.The Medical Journal of Australia|September 23, 2008
How do the Australian guidelines for lipid-lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999-2000Lei Chen, Sophie L Rogers, Stephen Colagiuri, et al.Journal of the American Heart Association|February 18, 2022
Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID StudyMalcolm West, Adrienne Kirby, Ralph A Stewart, et al.Pageof 15